Efficacy and safety of rituximab in children with difficult-to-treat nephrotic syndrome

Nephrology Dialysis Transplantation

Volumn 30, Issue 1, 2015, Pages 96-106

  Sinha, Aditi ^a   Bhatia, Divya ^a   Gulati, Ashima ^a   Rawat, Meenakshi ^a   Dinda, Amit K ^a   Hari, Pankaj ^a   Bagga, Arvind ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

B cell depletion; calcineurin inhibitors; focal segmental glomerulosclerosis; steroid resistance; steroid dependent nephrotic syndrome

Indexed keywords

CALCINEURIN INHIBITOR; CD19 ANTIGEN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; LEVAMISOLE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RITUXIMAB; STEROID; TACROLIMUS; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADOLESCENT; ADULT; ARTICLE; BODY HEIGHT; BODY MASS; CATARACT; CHICKENPOX; CHILD; CHILL; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE DURATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; FEVER; FOCAL GLOMERULOSCLEROSIS; GLAUCOMA; GLOMERULUS FILTRATION RATE; HEMATURIA; HUMAN; HUMORAL IMMUNE DEFICIENCY; HYPERGLYCEMIA; HYPERTENSION; INFUSION RELATED REACTION; LEUKOPENIA; MAJOR CLINICAL STUDY; MALARIA; MALE; NEPHROTIC SYNDROME; NEPHROTOXICITY; ONSET AGE; PERITONITIS; PSYCHOSIS; RECURRENCE FREE SURVIVAL; RECURRENCE RISK; REMISSION; RETREATMENT; SEIZURE; SORE THROAT; SYNOVITIS; TACHYPNEA; UNSPECIFIED SIDE EFFECT; URTICARIA; DRUG EFFECTS; DRUG RESISTANCE; MIDDLE AGED; MORTALITY; PROGNOSIS; RECURRENT DISEASE; RISK; SAFETY; SALVAGE THERAPY; SURVIVAL RATE; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; DRUG RESISTANCE; FEMALE; HUMANS; MALE; MIDDLE AGED; NEPHROTIC SYNDROME; ODDS RATIO; PROGNOSIS; RECURRENCE; REMISSION INDUCTION; SAFETY; SALVAGE THERAPY; SURVIVAL RATE; YOUNG ADULT;

EID: 84922448044     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfu267     Document Type: Article

References (34)

1. Kidney Disease Improving Global Outcomes (KDIGO). Steroid-sensitive nephrotic syndrome in children. Kidney Int 2012; (Suppl 2): 163-171
2. Indian Pediatric Nephrology Group. Management of steroid sensitive nephrotic syndrome: revised guidelines. Indian Pediatr 2008; 45: 203-214
3. Hodson EM, Willis NS, Craig JC. Interventions for idiopathic steroidresistant nephrotic syndrome in children. Cochrane Database Syst Rev 2010; 11: CD003594
4. Colquitt JL, Kirby J, Green C et al. The clinical effectiveness and costeffectiveness of treatments for children with idiopathic steroid-resistant nephrotic syndrome: a systematic review. Health Technol Assess 2007; 11: 1-93
5. El-Husseini A, El-Basuony F, Mahmoud I et al. Long-term effects of cyclosporine in children with idiopathic nephrotic syndrome: a singlecentre experience. Nephrol Dial Transplant 2005; 20: 2433-2438
6. Iijima K, Hamahira K, Tanaka R et al. Risk factors for cyclosporineinduced tubulointerstitial lesions in children with minimal change nephrotic syndrome. Kidney Int 2002; 61: 1801-1805
7. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group: KDIGO Clinical practice guideline for glomerulonephritis. Kidney Int 2012; (Suppl 2): 139-274
8. Sinha A, Bagga A. Rituximab therapy in nephrotic syndrome: implications for patients management. Nat Rev Nephrol 2013; 9: 154-169
9. Bagga A, Sinha A, Moudgil A. Rituximab in patients with the steroidresistant nephrotic syndrome. N Engl J Med 2007; 356: 2751-2752
10. Gulati A, Sinha A, Jordan S et al. Efficacy and safety of treatment with rituximab for difficult steroid resistant and dependent nephrotic syndrome: multicentric report. Clin J Am Soc Nephrol 2010; 5: 2207-2212
11. Fujinaga S, Hirano D, Nishizaki N et al. Single infusion of rituximab for persistent steroid-dependent minimal-change nephrotic syndrome after long-term cyclosporine. Pediatr Nephrol 2010; 25, 539-544
12. Ito S, Kamei K, Ogura M et al. Survey of rituximab treatment for childhood- onset refractory nephrotic syndrome. Pediatr Nephrol 2013; 28: 257-264
13. Kemper MJ, Gellermann J, Habbig S et al. Long-term follow-up after rituximab for steroid-dependent idiopathic nephrotic syndrome. Nephrol Dial Transplant 2012; 27: 1910-1915.
14. Prytula A, Iijima K, Kamei K et al. Rituximab in refractory nephrotic syndrome. Pediatr Nephrol 2010; 25: 461-468
15. Sellier-Leclerc AL, Macher MA, Loirat C et al. Rituximab efficiency in children with steroid-dependent nephrotic syndrome. Pediatr Nephrol 2010; 25:1109-1115
16. Guigonis V, Dallocchio A, Baudouin V et al. Rituximab treatment for severe steroid- or cyclosporine-dependent nephrotic syndrome: a multicentric series of 22 cases. Pediatr Nephrol 2008; 23: 1269-1279
17. Iijima K, Sako M, Nozu K et al. Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebocontrolled trial. Lancet 2014; doi: 10.1016/S0140-6736(14)60541-9.
18. Magnasco A, Ravani P, Edefonti A et al. Rituximab in children with resistant idiopathic nephrotic syndrome. J Am Soc Nephrol 2012; 23, 1117-1124
19. Ruggenenti P, Ruggiero B, Cravedi P et al. for the Rituximab in Nephrotic Syndrome of Steroid-Dependent or Frequently Relapsing Minimal Change Disease Or Focal Segmental Glomerulosclerosis (NEMO) Study Group. Rituximab in steroid-dependent or frequently relapsing idiopathic nephrotic syndrome. J Am Soc Nephrol 2014; 25: 850-863
20. Ravani P, Magnasco A, Edefonti A et al. Short-term effects of rituximab in children with steroid- and calcineurin-dependent nephrotic syndrome: a randomized controlled trial. Clin J Am Soc Nephrol 2011; 6: 1308-1315
21. Sinha A, Bagga A, Gulati A et al. Short-term efficacy of rituximab versus tacrolimus in steroid-dependent nephrotic syndrome. Pediatr Nephrol 2012; 27: 235-241 http//www.cdc.gov/growthcharts (23 February 2014, date last accessed).
22. Schwartz GJ, Muñoz A, Schneider MF et al. New equations to estimate GFR in children with CKD. J Am Soc Nephrol 2009; 20: 629-637
23. Hoxha E, Stahl RA, Harendza S. Rituximab in adult patients with immunosuppressive dependent minimal change disease. Clin Nephrol 2011; 76: 151-158
24. Kronbichler A, Kerschbaum J, Fernandez-Fresnedo G et al. Rituximab treatment for relapsing minimal change disease and focal segmental glomerulosclerosis: a systematic review. Am J Nephrol 2014; 39: 322-330
25. Sato M, Ito S, Ogura M et al. Impact of rituximab on height and weight in children with refractory steroid-dependent nephrotic syndrome. Pediatr Nephrol 2014; 29: 1373-1379
26. Fujinaga S, Hirano D. Risk factors for early relapse during maintenance therapy after a single infusion of rituximab in children with steroiddependent nephrotic syndrome. Pediatr Nephrol 2014; 29: 491-492
27. Sellier-Leclerc AL, Baudouin V, Kwon T et al. Rituximab in steroiddependent idiopathic nephrotic syndrome in childhood-follow-up after CD19 recovery. Nephrol Dial Transplant 2012; 27: 1083-1089
28. Kimata T, Hasui M, Kino J et al. Novel use of rituximab for steroiddependent nephrotic syndrome in children. Am J Nephrol 2013; 38: 483-488
29. Ahn YH, Kang HG, Lee JM et al. Development of antirituximab antibodies in children with nephrotic syndrome. Pediatr Nephrol 2014; 29: 1461-1464
30. Fujinaga S, Someya T, Watanabe T et al. Cyclosporine versus mycophenolate mofetil for maintenance of remission of steroid-dependent nephrotic syndrome after a single infusion of rituximab. Eur J Pediatr 2013; 172: 513-518
31. Ito S, Kamei K, Ogura M et al. Maintenance therapy with mycophenolate mofetil after rituximab in pediatric patients with steroid-dependent nephrotic syndrome. Pediatr Nephrol 2011; 26: 1823-1828
32. Gulati A, Sinha A, Gupta A et al. Treatment with tacrolimus and prednisolone is preferable to intravenous cyclophosphamide as the initial therapy for children with steroid-resistant nephrotic syndrome. Kidney Int 2012; 82: 1130-1135
33. Lombel RM, Hodson EM, Gipson DS. Treatment of steroid-resistant nephrotic syndrome in children: new guidelines from KDIGO. Pediatr Nephrol 2013; 28: 409-414
34. Gellermann J, Ehrich JH, Querfeld U. Sequential maintenance therapy with cyclosporin A and mycophenolate mofetil for sustained remission of childhood steroid-resistant nephrotic syndrome. Nephrol Dial Transplant 2012; 27: 1970-1978